Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells

A M Aslanian, M S Kilberg, A M Aslanian, M S Kilberg

Abstract

Childhood acute lymphoblastic leukaemia is treated by combination chemotherapy with a number of drugs, almost always including the enzyme L-asparaginase (ASNase). Although the initial remission rate is quite high, relapse and associated drug resistance remain a problem. In vitro studies have demonstrated an adaptive increase in asparagine synthetase (AS) expression in ASNase-resistant cells, which is believed to permit ASNase-resistant human leukaemia cells to survive in vivo. The present results, obtained with ASNase-sensitive and -resistant human MOLT-4 leukaemia cell lines, illustrate that several other adaptive processes occur to provide sufficient amounts of the AS substrates, aspartate and glutamine, required to support this increased enzymic activity. In both cell populations, aspartate is derived almost exclusively from intracellular sources, whereas the necessary glutamine arises from both intracellular and extracellular sources. Transport of glutamine into ASNase-resistant cells is significantly enhanced compared with the parental cells, whereas amino acid efflux (e.g. asparagine) is reduced. Most of the adaptive change for the amino acid transporters, Systems A, ASC and L, is rapidly (12 h) reversed following ASNase removal. The enzymic activity of glutamine synthetase is also enhanced in ASNase-resistant cells by a post-transcriptional mechanism. The results demonstrate that there are several sites of metabolic adaptation in ASNase-treated leukaemia cells that serve to promote the replenishment of both glutamine and asparagine.

References

    1. Biochem Biophys Res Commun. 1968 Apr 5;31(1):43-7
    1. Hepatology. 1999 Aug;30(2):437-44
    1. J Biol Chem. 2000 Jun 2;275(22):16473-7
    1. J Biol Chem. 1967 Nov 25;242(22):5237-46
    1. Cancer Res. 1969 Jan;29(1):183-7
    1. J Biol Chem. 1969 Mar 25;244(6):1510-20
    1. Cancer. 1970 Feb;25(2):306-20
    1. Cancer Res. 1971 Jul;31(7):942-9
    1. Cancer. 1971 Oct;28(4):819-24
    1. J Cell Physiol. 1984 Aug;120(2):197-203
    1. J Clin Invest. 1988 Jan;81(1):32-8
    1. Am J Physiol. 1988 Sep;255(3 Pt 1):C261-70
    1. J Membr Biol. 1988 Aug;104(1):1-20
    1. Leukemia. 1989 Apr;3(4):294-7
    1. Cancer Res. 1989 Aug 1;49(15):4363-8
    1. Cancer. 1990 Jun 15;65(12):2615-8
    1. Cancer Res. 1991 Feb 1;51(3):985-9
    1. Cancer Chemother Pharmacol. 1993;32(2):129-33
    1. J Biol Chem. 1993 Jul 25;268(21):15351-5
    1. Annu Rev Nutr. 1993;13:137-65
    1. J Clin Oncol. 1994 Jun;12(6):1312-22
    1. Leukemia. 1995 Feb;9(2):360-1
    1. Blood. 1995 Apr 15;85(8):2025-37
    1. Exp Cell Res. 1995 Oct;220(2):283-91
    1. Cancer. 1995 Dec 15;76(12):2393-417
    1. Annu Rev Biochem. 1996;65:305-36
    1. Crit Rev Oncol Hematol. 1997 Jan;25(1):11-26
    1. Am J Physiol. 1997 May;272(5 Pt 1):C1691-9
    1. Blood. 1997 Oct 1;90(7):2723-9
    1. Leukemia. 1997 Nov;11(11):1858-61
    1. Anticancer Res. 1998 Mar-Apr;18(2A):727-37
    1. Blood. 1998 Jul 1;92(1):259-66
    1. Prog Nucleic Acid Res Mol Biol. 1998;61:243-308
    1. Crit Rev Oncol Hematol. 1998 Aug;28(2):97-113
    1. Physiol Rev. 1998 Oct;78(4):969-1054
    1. Am J Physiol. 1999 Jun;276(6 Pt 1):E1136-45
    1. J Exp Med. 1968 Jun 1;127(6):1055-72

Source: PubMed

3
订阅